AGENUS INC · Biotech

AGEN

High riskNext report: Nov 5 (confirmed)

View price ↗

The short version

A company still losing money with growing sales, with high risk. Institutions are adding.

Going well

Sales up 34% in the latest quarter vs a year ago
Sales up 10% last year

Watch out for

Less than a month of cash left at its current burn
Owes more than it owns (negative equity)
Share count growing 28.3% a year (dilution)

Money moves

No insider buying or selling in the last 30 days
Institutions added 55% to their holdings in the quarter ending June 2026 (63 bought, 33 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$6.16-2.7% that day

Company value: $277M; Share price times all shares
Price vs profit (P/E): 2.4x; You pay about $2 for each $1 of yearly profit
Price vs sales: 2.1x; Company value is 2.1 times a year of sales
Cash vs value: 7%; Cash as a share of company value
Debt vs value: 16%; Debt as a share of company value

From AGEN's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$34.5M+34% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $132.7M, up 30% from the 12 months before. Over 5 years, sales grew about 5.3% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of AGEN. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +30% a yearProfit margin50%Last 12 months: 69.3%P/E at the end8xToday: 2.4x. Many steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$493M

Profit in 5 years$246M

Price these guesses point to$27.18+341% vs $6.16 todayAbout +35% a year, before dividends

What today's price needs: with a 50% margin and a 8x P/E, sales could shrink about 3.4% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

0/5Weak

MissDebt under half of equityNot relying on borrowed money.Owes more than it owns
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-2.7%
MissProfitable every yearSteady profits, not one good year.0 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$77.2M
MissShare count not growingNot diluting owners. Falling means buybacks.+111.1% in 3 years

Revenue: $114.2M; +10.4% vs prior year
5-year growth: +5.3%/yr; revenue, per year
Total debt: $44.7M
Current ratio: 0.41x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, gross margin 40%+. A checklist is a starting point for research, not a verdict.